Active surveillance of localized prostate cancer.: Significance of prostate core needle biopsies

被引:0
|
作者
Rueschoff, J. [1 ]
Middel, P. [1 ]
Albers, P. [2 ]
机构
[1] Inst Pathol Nordhessen, D-34131 Kassel, Germany
[2] Klinikum Kassel GmbH, Urol Klin, Kassel, Germany
来源
PATHOLOGE | 2008年 / 29卷 / 05期
关键词
insignificant prostate cancer; active surveillance; Gleason score; core needle biopsy; improved pre-embedding;
D O I
10.1007/s00292-008-1013-3
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Today, more than 80% of men diagnosed with prostate cancer (PCA) by PSA screening do not die from the sequelae of their disease. About 70% present with early, organ-confined cancer and almost half of them are small (< 5 cm(3)) without evidence of progression over years (insignificant PCA). It is assumed that screening brings the diagnosis of PCA forward by about 9 years and that in almost one third of these cases immediate radical prostatectomy or radiotherapy would result in overtreatment. Thus, the treatment strategy of "active surveillance" with selective but delayed intervention for patients with organ-confined PCA could be an attractive alternative to the known curative therapy options. However, a prerequisite of such a therapeutic approach would be a precise identification of patients at high risk for cancer progression. Careful work-up of prostate core needle biopsies including improved pre-embedding preparation and detailed interpretation are of the utmost importance. A Gleason score <= 6 and tumor in only one or two cores are considered predictive of organ-confined cancer. Pathologists should concentrate on correct Gleason scoring in core needle biopsies and identification of lesions that exclude a patient from active surveillance.
引用
收藏
页码:339 / 347
页数:9
相关论文
共 50 条
  • [1] Active surveillance of localized prostate cancer: Significance of prostate core needle biopsies [Active surveillance des lokalisierten prostatakarzinoms: Wertigkeit der prostatastanzbiopsie]
    Rüschoff J.
    Middel P.
    Albers P.
    Der Pathologe, 2008, 29 (5): : 339 - 347
  • [2] Regional differences in the utilization of active surveillance in localized prostate cancer.
    Scherzer, Nickolas David
    Srivastav, Sudesh
    DiBiase, Steven J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Active surveillance for localized prostate cancer
    Tinay, Ilker
    Turkeri, Levent
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2012, 11 (02): : 114 - 118
  • [4] Active surveillance for localized prostate cancer
    Staerman, F.
    Peyromaure, M.
    Irani, J.
    Gaschignard, N.
    Mottet, N.
    Soulie, M.
    Salomon, L.
    PROGRES EN UROLOGIE, 2011, 21 (07): : 448 - 454
  • [5] Active surveillance for localized prostate cancer
    Drouin, S. J.
    Roupret, M.
    Hamdy, F.
    Mottet, N.
    PROGRES EN UROLOGIE, 2010, 20 : S181 - S185
  • [6] Significance of prior negative needle biopsies in men subsequently diagnosed with prostate cancer.
    Carter, HB
    Walsh, PC
    Epstein, JI
    LABORATORY INVESTIGATION, 1999, 79 (01) : 91A - 91A
  • [7] Active treatment or surveillance in prostate cancer.
    Irani, Jacques
    PROGRES EN UROLOGIE, 2007, 17 (01): : 98 - 98
  • [8] Place of surveillance in the treatment of localized prostate cancer.
    Ravery, V
    Boccon-Gibod, L
    PROGRES EN UROLOGIE, 1999, 9 (02): : 225 - 230
  • [9] Active Surveillance or Active Treatment in Localized Prostate Cancer?
    Weissbach, Lothar
    Altwein, Jens
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2009, 106 (22): : 371 - I
  • [10] Active surveillance and surgery in localized prostate cancer
    Kwon, O.
    Hong, S. K.
    MINERVA UROLOGICA E NEFROLOGICA, 2014, 66 (03) : 175 - 187